6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. (Q37855902)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Serena Massari

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Violetta Cecchetti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Oriana Tabarrini

1

1 reference

24 August 2017

Serena Massari

2

1 reference

24 August 2017

Violetta Cecchetti

3

1 reference

24 August 2017

publication date

1 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

Future Medicinal Chemistry

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

1161-1180

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426162%20AND%20SRC:MED&resulttype=core&format=json

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Cellular reservoirs of HIV-1 and their role in viral persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Eradication of HIV: current challenges and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Resistance to novel drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Controlling the elongation phase of transcription with P-TEFb

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

A fluoroquinolone (DR-3355) protects human lymphocyte cell lines from HIV-1-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Ciprofloxacin Inhibits Activation of Latent Human Immunodeficiency Virus Type 1 in Chronically Infected Promonocytic U1 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

6-Aminoquinolones as new potential anti-HIV agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Strategies for the Design of Rna-Binding Small Molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Synthesis and biological evaluation of 2-phenylquinolones targeted at Tat/TAR recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Structure modifications of 6-aminoquinolones with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Structure-activity relationship study on anti-HIV 6-desfluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

QSAR study and VolSurf characterization of anti-HIV quinolone library.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Antiviral properties of quinolone-based drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: a new class of anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibition of human immunodeficiency virus type 1 transcription by N-aminoimidazole derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

HIV integrase inhibitors as therapeutic agents in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Antiviral 6-amino-quinolones: molecular basis for potency and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

A 6-aminoquinolone compound, WC5, with potent and selective anti-human cytomegalovirus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Recent status of HIV-1 gene expression inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Targeting host factors: A novel rationale for the management of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Targeting the HIV Trans‐Activation Responsive Region—Approaches Towards RNA‐Binding Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibitors of HIV-1 gene expression and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibitors of HIV-1 Tat-mediated transactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Discoveries of Tat-TAR interaction inhibitors for HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

A New Class of HIV-1 Tat Antagonist Acting through Tat−TAR Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Synthesis and testing of a focused phenothiazine library for binding to HIV-1 TAR RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Antiviral activity of CYC202 in HIV-1-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibition of the tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative k-37.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Inhibition of porcine endogenous retrovirus (PERV) replication by HIV-1 gene expression inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

The Synthesis of Certain Substituted Quinolines and 5,6-Benzoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

Studies on anti-HIV quinolones: New insights on the C-6 position

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208

6-Aminoquinolones: A New Class of Quinolone Antibacterials?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.208